Revium Rx 8-K, filed Jun 1, 2026
Revium Rx. (RVRC)
About this 8-K
Revium Rx filed this 8-K on June 1, 2026, reporting on events of May 27, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact Name of Registrant as Specified in its Charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
| n/a |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
Resignation of Mr. Arie Gordashnikov from his position as Chief Financial Officer
On May 27, 2026, Mr. Arie Gordashnikov resigned from his position as Chief Financial Officer of Revium Rx. (“we,” “us,” “our,” “Revium” or the “company”) and of its subsidiaries, effective immediately. Mr. Gordashnikov’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Appointment of Mr. Igor Bluvstein as Chief Financial Officer
On May 27, 2026, our Board of Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.
Prior to his appointment as Chief Financial Officer, from 2024 through 2025, Mr. Bluvstein served as Chief Financial Officer of Argent BioPharma Ltd. (ASX: RGT; LSE: RGT; OTCQB: RGTLF) and from 2022 through 2024 as Chief Financial Officer of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD). Mr. Bluvstein, 44, has over seventeen (17) years of experience in financial leadership across the pharmaceutical, digital health, biotechnology, e-commerce, and petrochemical industries. Earlier in his career, from 2020 through 2022 he served as Chief Financial & Operations Officer of MDD Group and from 2016 through 2020 as Regional Chief Financial Officer at Frutarom Industries Ltd. (acquired by International Flavors & Fragrances Inc. (NYSE: IFF)). Mr. Bluvstein holds a Bachelor of Arts in Accounting and Economics from the Open University of Israel. He is a Certified Public Accountant (CPA).
In connection with his appointment, Mr. Bluvstein will receive a monthly retainer of NIS17,000 plus VAT.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVIUM Rx. | |||
| June 1, 2026 | By: | /s/ Amir Avraham | |
| Name: | Amir Avraham | ||
| Title: | Chief Executive Officer | ||
2